Core Viewpoint - The stock of Keren Biotechnology-B (06990) opened over 5% higher and is currently up 5.37%, trading at 483 HKD with a transaction volume of 1.5939 million HKD, following the announcement of multiple clinical research results at the ESMO Congress held in Berlin from October 17 to 21, 2025 [1]. Group 1 - Keren Biotechnology-B announced the presentation of several clinical research results at the 2025 European Society for Medical Oncology (ESMO) Congress [1]. - The clinical data includes findings related to the TROP2-targeted antibody-drug conjugate (ADC) sac-TMT (also known as Jiatailai) [1]. - Additional data presented involves the HER2-targeted ADC A166 (also known as Shuitailai) and the Claudin18.2 ADC SKB315 [1].